source
- Undecimal Bio raises $18 million to expand siRNA platform beyond liver diseasesUndecimal Bio, founded by Yaniv Erlich and Shaul Ilan, announced a new financing round that brings in $18 million. The capital will support the company’s effort to develop siRNA therapeutics for ta…
- Merck's diabetic eye-disease drug hits primary goal but faces commercial doubtsMerck announced results from a pivotal trial of its ophthalmology candidate remigromig, aimed at treating diabetic macular edema. The study achieved its primary endpoint, demonstrating that remigr…